(redirected from Somatuline)


(lan-ree-o-tide) ,

Somatuline Depot

(trade name)


Therapeutic: hormones
Pharmacologic: somatostatin analogues
Pregnancy Category: C


Long-term management of acromegaly which cannot be treated by or has not responded to surgery and/or radiation therapy.


Acts as an analog of somatostatin, inhibiting growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in patients with acromegaly.

Therapeutic effects

Decreased levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) in acromegalic patients resulting in decreased manifestations of acromegaly.


Absorption: Following subcut administration, lanreotide precipitates in body tissues acting as a depot formulation from which drug is slowly released (75% bioavailability).
Distribution: Unknown.
Metabolism and Excretion: Minimal renal/fecal excretion, some biliary excretion.
Half-life: 23–30 days.

Time/action profile

Subcutunknownfirst 24 hr1 mo


Contraindicated in: Obstetric: Lactation.
Use Cautiously in: Diabetic patients; Underlying heart disease, especially bradycardia; Obstetric: Use only if maternal benefit outweighs risk to fetus; Pediatric: Safety not established.

Adverse Reactions/Side Effects


  • bradycardia
  • hypertension


  • pancreatitis (life-threatening)
  • abdominal pain (most frequent)
  • diarrhea (most frequent)
  • gallstones (most frequent)


  • hyperglycemia
  • hypoglycemia


  • anemia


  • injection site reactions (most frequent)


Drug-Drug interaction

↑ risk of bradycardia with other drugs that may cause ↓ heart rate including beta-blockers.May ↓ absorption of cyclosporine (dose adjustment may be necessary).May alter the effects of antidiabetic agents (monitor blood sugar).May ↓ activity or CYP450 enzyme system, use cautiously with drugs metabolized by that system, including quinidine.


Subcutaneous (Adults) 90 mg every 4 week for 3 mo, further adjustments are made on the basis of GH and IGF1 levels as follows: GH > 1 to ≤2.5 ng/mL, IGF-1 normal with good symptom control—maintain dose at 90 mg every 4 wk;GH >2.5 ng/mL, IGF-1 elevated and/or uncontrolled symptoms—↑ dose to 120 mg every 4 wk; GH ≤1 mg/mL, IGF-1 symptoms currently controlled —↓ dose to 60 mg every 4 wk.

Hepatic/Renal Impairment

Subcutaneous (Adults) Moderate to severe hepatic or renal impairment—60 mg every 4 wk; further adjustments are made on the basis of GH and IGF1 levels.


Semi-solid in pre-filled syringes: 60 mg, 90 mg, 120 mg

Nursing implications

Nursing assessment

  • Assess for GI side effects (diarrhea, abdominal pain, nausea, gas, constipation); usually decrease with continued treatment.
  • Lab Test Considerations: Monitor serum growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels every 3 mo.
    • May cause hyperglycemia or hypoglycemia. Monitor blood glucose when therapy is initiated and when dose is altered and adjust antidiabetic treatment accordingly.
    • May cause slight ↓ thyroid function; monitor as clinically indicated.
    • May cause anemia.

Potential Nursing Diagnoses

Risk for disproportionate growth (Indications)
Deficient knowledge, related to medication regimen (Patient/Family Teaching)


  • Subcutaneous: Store in refrigerator and protect from light. Remove sealed pouch from refrigerator 30 min prior to injection; allow to reach room temperature. Keep pouch sealed until injection. Administer deep into subcutaneous tissue of superior external buttock. Do not fold skin; insert needle perpendicular to skin, rapidly to full length. Alternate injection between right and left side. May cause injection site reactions (pain, injection site mass); decrease with continued therapy. Syringe is for single use; do not use after expiration date.

Patient/Family Teaching

  • Explain purpose of lanreotide to patient. Advise patient to read Patient Information before receiving first injection and before each monthly injection in case of new information. If an injection is missed, consult health care professional.
  • Instruct patient to notify health care professional if unusual symptoms develop or known symptoms persist or worsen.
  • Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care professional before taking other Rx, OTC, or herbal products.
  • Advise patient to notify health care professional if pregnancy is planned or suspected or if breastfeeding.

Evaluation/Desired Outcomes

  • Decreased levels of growth hormone (GH) and insulin-like growth factor-1 (IGF-1).


an antigrowth hormone.
indication This drug is used to treat acromegaly in patients having an inadequate response to other treatments.
contraindications Known hypersensitivity to this drug or latex allergy prohibits its use.


A somatostatin analogue drug used to treat the growth disorder acromegaly prior to surgery on the pituitary gland. Somatostatin is a hormone produced by the hypothalamus of the brain, which inhibits the release of the natural growth hormone, somatotropin as well as of other pituitary gland-stimulating hormones. Brand name: Somatuline LA.
References in periodicals archive ?
9% reflecting continued Somatuline momentum and increasing contribution from the Cabometyx and Onivyde launches, and Consumer Healthcare back to growth at 1.
Three additional posters will be presented focused on neuroendocrine tumors or Somatuline Depot Injection 120mg.
M2 EQUITYBITES-July 3, 2017-Ipsen and Teijin Pharma receive Japanese approval to extend indication of Somatuline
M2 PHARMA-July 3, 2017-Ipsen and Teijin Pharma receive Japanese approval to extend indication of Somatuline
He played a key role in the approval of Somatuline for the treatment of neuroendocrine tumours, our partnership with Exelixis for Cabometyx and the acquisition of Onivyde.
Furthermore, there are significant commercial synergies to be realized by integrating the Onivyde franchise with the existing Ipsen US oncology commercial infrastructure, which has strong expertise and a proven track record with Somatuline.
5 mg Comprime BoEte de 28 187,00 66,70 93,35 ZOCOR 40mg Comprime BoEte de 28 467,00 232,00 258,28 BRICANYL 5 mg/2 ml Solution pour nebulisation BoEte de 50 recipients unisdoses 384,50 200,00 230,57 ARAVA 10 mg Comprime pellicule Flacon de 30 1 051,90 556,00 847,67 ZECLAR 500 mg comprime pellicule boEte de 14 360,00 192,20 231,69 VENTOLINE 100 mcg/dose Suspension pour inhalation en Flacon pressurise Flacon de 200doses 56,30 45,30 56,77 Comparaison du nouveau prix public de vente au Maroc de certains medicaments avec celui de la Tunisie Nom du Medicament Prix Public Maroc en Dirham avant revision Prix Public de Vente en Dirham apres revision Prix Public En Tunisie (en DH) NOVONORM 0,5 mg Comprime BoEte de 30 108,00 50,20 61,34 SOMATULINE LP 90mg Solution injectable (I.
Its development strategy is supported by four franchises: neurology / Dysport, endocrinology / Somatuline, uro-oncology / Decapeptyland hemophilia.
In the United States, the prolonged-release formulation of lanreotide, which the label says is a synthetic octapeptide with a biological activity similar to naturally occurring somatostatin, is being marketed as Somatuline Depot.
In the United States, the prolonged-release formulation of lanreotide, a synthetic octapeptide with biologic activity similar to that of naturally occurring somatostatin, is being marketed as Somatuline Depot.
Brisbane CA) won approval for its medicine, Somatuline Depot, as a treatment option for patients with acromegaly, a condition marked by excessive growth of the head and extremities.
5 mg/ml 50-100 mcg subcut acetate (20 ml vial) q 8 hr 1 mg/ml (5 ml vial) Octreotide Sandostatin 10 mg vial 20-40 mg IM q acetate LAR Depot 20 mg vial 30 days 30 mg vial Lanreotide-SR Somatuline 0.